JPWO2021260092A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021260092A5 JPWO2021260092A5 JP2022579869A JP2022579869A JPWO2021260092A5 JP WO2021260092 A5 JPWO2021260092 A5 JP WO2021260092A5 JP 2022579869 A JP2022579869 A JP 2022579869A JP 2022579869 A JP2022579869 A JP 2022579869A JP WO2021260092 A5 JPWO2021260092 A5 JP WO2021260092A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- fluoro
- quinoxalin
- piperazin
- carboxamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063044095P | 2020-06-25 | 2020-06-25 | |
| US63/044,095 | 2020-06-25 | ||
| US202063120351P | 2020-12-02 | 2020-12-02 | |
| US63/120,351 | 2020-12-02 | ||
| PCT/EP2021/067304 WO2021260092A1 (en) | 2020-06-25 | 2021-06-24 | Quinoxaline derivatives as anti-cancer drugs |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023532257A JP2023532257A (ja) | 2023-07-27 |
| JP2023532257A5 JP2023532257A5 (https=) | 2024-06-19 |
| JPWO2021260092A5 true JPWO2021260092A5 (https=) | 2024-06-19 |
| JP7769650B2 JP7769650B2 (ja) | 2025-11-13 |
Family
ID=76662494
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022579869A Active JP7769650B2 (ja) | 2020-06-25 | 2021-06-24 | 抗がん薬としてのキノキサリン誘導体 |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US11795158B2 (https=) |
| EP (1) | EP4172152A1 (https=) |
| JP (1) | JP7769650B2 (https=) |
| KR (1) | KR20230026450A (https=) |
| CN (2) | CN115768760B (https=) |
| AU (1) | AU2021295423B2 (https=) |
| BR (1) | BR112022025435A2 (https=) |
| CA (1) | CA3186996A1 (https=) |
| CL (1) | CL2022003711A1 (https=) |
| CO (1) | CO2023000186A2 (https=) |
| CR (1) | CR20230024A (https=) |
| DO (1) | DOP2022000288A (https=) |
| EC (1) | ECSP23005059A (https=) |
| IL (1) | IL299123B2 (https=) |
| MX (1) | MX2022015435A (https=) |
| PE (1) | PE20231081A1 (https=) |
| SA (1) | SA522441701B1 (https=) |
| TW (1) | TW202218664A (https=) |
| UA (1) | UA130043C2 (https=) |
| UY (1) | UY39296A (https=) |
| WO (1) | WO2021260092A1 (https=) |
| ZA (1) | ZA202300924B (https=) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022000711A (es) | 2019-07-19 | 2022-02-23 | Astrazeneca Ab | Inhibidores de parp1. |
| US11795158B2 (en) * | 2020-06-25 | 2023-10-24 | Astrazeneca Ab | Chemical compounds |
| US12280049B2 (en) * | 2020-08-04 | 2025-04-22 | Astrazeneca Ab | Methods of delaying pain progression and treating prostate cancer |
| TW202309025A (zh) | 2021-04-19 | 2023-03-01 | 美商辛瑟拉股份有限公司 | Parp1抑制劑及其用途 |
| TW202304911A (zh) * | 2021-04-23 | 2023-02-01 | 大陸商南京明德新藥研發有限公司 | 吡啶醯胺類化合物 |
| EP4349836A4 (en) | 2021-05-24 | 2024-10-30 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, ITS PREPARATION METHOD AND ITS APPLICATION IN DRUGS |
| JP2024522736A (ja) * | 2021-06-16 | 2024-06-21 | リペア セラピューティクス インコーポレイテッド | がん治療のためのｐａｒｐ阻害剤と組み合わせたａｔｒ阻害剤の使用 |
| US20240366584A1 (en) | 2021-06-21 | 2024-11-07 | Tesaro, Inc. | Combination treatment of cancer with a parp inhibitor and a lipophilic statin |
| AU2022334408A1 (en) | 2021-08-27 | 2024-02-15 | Impact Therapeutics (Shanghai), Inc. | Substituted tricyclic compounds as parp inhibitors and use thereof |
| WO2023046034A1 (zh) * | 2021-09-22 | 2023-03-30 | 明慧医药（杭州）有限公司 | 一种含氮杂环化合物、其制备方法、其中间体及其应用 |
| WO2023046158A1 (zh) * | 2021-09-26 | 2023-03-30 | 张文燕 | 氮杂喹啉酮类化合物及其医药用途 |
| WO2023046149A1 (zh) * | 2021-09-26 | 2023-03-30 | 张文燕 | 喹喔啉类化合物及其医药用途 |
| US20240391937A1 (en) * | 2021-09-30 | 2024-11-28 | Xizang Haisco Pharmaceutical Co., Ltd. | Bicyclic derivative parp inhibitor and use thereof |
| WO2023051716A1 (zh) * | 2021-09-30 | 2023-04-06 | 海思科医药集团股份有限公司 | 杂芳基衍生物parp抑制剂及其用途 |
| US20230159525A1 (en) | 2021-10-01 | 2023-05-25 | Xinthera, Inc. | Azetidine and pyrrolidine parp1 inhibitors and uses thereof |
| JP7762306B2 (ja) | 2021-11-19 | 2025-10-29 | 康百達（四川）生物医薬科技有限公司 | 選択的ｐａｒｐ１阻害剤およびその用途 |
| IL313661A (en) * | 2021-12-21 | 2024-08-01 | Astrazeneca Ab | Methods of treating brain tumours and neuroblastomas |
| WO2023134647A1 (zh) * | 2022-01-13 | 2023-07-20 | 优领医药科技(香港)有限公司 | 含哌嗪并环类衍生物、其药学上可接受的盐及其制备方法和应用 |
| WO2023138541A1 (zh) * | 2022-01-20 | 2023-07-27 | 微境生物医药科技(上海)有限公司 | 吡啶酰胺类parp抑制剂、及其制备方法和医药用途 |
| AU2023209820B2 (en) | 2022-01-21 | 2024-10-10 | Xinthera, Inc. | Parp1 inhibitors and uses thereof |
| US20260098024A1 (en) * | 2022-01-27 | 2026-04-09 | Xinthera, Inc. | Parp1 inhibitors and uses thereof |
| WO2023146960A1 (en) * | 2022-01-28 | 2023-08-03 | Xinthera, Inc. | Parp1 inhibitors and uses thereof |
| CN116693501B (zh) * | 2022-02-10 | 2025-12-19 | 康百达（四川）生物医药科技有限公司 | 一种喹唑啉酮衍生物及其在医药上的应用 |
| KR20240161147A (ko) | 2022-03-14 | 2024-11-12 | 슬랩 파마슈티컬스 엘엘씨 | 다중 사이클릭 화합물 |
| WO2023201338A1 (en) | 2022-04-15 | 2023-10-19 | Ideaya Biosciences, Inc. | Combination therapy comprising a mat2a inhibitor and a parp inhibitor |
| FI4497438T3 (fi) | 2022-04-28 | 2025-10-20 | Xinthera Inc | Trisyklisiä parp1:n estäjiä ja niiden käyttötapoja |
| WO2023207284A1 (en) * | 2022-04-28 | 2023-11-02 | Ningbo Newbay Technology Development Co., Ltd | Piperazine derivatives as parp1 inhibitiors |
| CN119110801A (zh) * | 2022-05-07 | 2024-12-10 | 南京明德新药研发有限公司 | 选择性抑制parp1的氟代喹喔啉酮衍生物 |
| CN119255995A (zh) | 2022-05-25 | 2025-01-03 | 西藏海思科制药有限公司 | 双环衍生物parp抑制剂及其用途 |
| US20250346573A1 (en) * | 2022-06-02 | 2025-11-13 | Chengdu Easton Biopharmaceuticals Co., Ltd. | Azaquinolinone derivative, preparation method therefor and use thereof |
| IL317573A (en) | 2022-06-15 | 2025-02-01 | Astrazeneca Ab | Combination therapy for cancer treatment |
| CN115919859B (zh) * | 2022-07-14 | 2024-01-05 | 四川海思科制药有限公司 | 一种杂芳基衍生物的药物组合物及其在医药上的应用 |
| CN117658983A (zh) * | 2022-09-01 | 2024-03-08 | 浙江文达医药科技有限公司 | 选择性parp1抑制剂 |
| TW202416977A (zh) * | 2022-09-30 | 2024-05-01 | 大陸商中國醫藥研究開發中心有限公司 | 含氮雜環類化合物及其醫藥用途 |
| US20240174669A1 (en) * | 2022-10-06 | 2024-05-30 | Xinthera, Inc. | Crystalline forms of a parp1 inhibitor |
| WO2024083218A1 (zh) * | 2022-10-20 | 2024-04-25 | 成都赜灵生物医药科技有限公司 | 取代四氢吡啶类化合物及其用途 |
| CN120035596A (zh) | 2022-11-23 | 2025-05-23 | 江苏恒瑞医药股份有限公司 | 一种含氮杂环类化合物的可药用盐、晶型及制备方法 |
| IL321260A (en) | 2022-12-06 | 2025-08-01 | Astrazeneca Ab | Polq inhibitors |
| EP4729514A1 (en) | 2023-06-14 | 2026-04-22 | Haisco Pharmaceutical Group Co., Ltd. | Bicyclic derivative parp inhibitor and use thereof |
| WO2025067417A1 (zh) | 2023-09-28 | 2025-04-03 | 成都赜灵生物医药科技有限公司 | 并内酰胺环类化合物及其用途 |
| WO2025092973A1 (zh) * | 2023-11-03 | 2025-05-08 | 成都赜灵生物医药科技有限公司 | Parp1靶向化合物及其用途 |
| TW202535479A (zh) | 2023-12-05 | 2025-09-16 | 英商阿斯特捷利康英國股份有限公司 | 抗體藥物結合物與血腦屏障穿透性ｐａｒｐ１選擇性抑制劑之組合 |
| CN120398887A (zh) * | 2024-01-31 | 2025-08-01 | 西藏海思科制药有限公司 | 一种双环衍生物parp抑制剂的晶型及其制备方法和应用 |
| KR20250128449A (ko) | 2024-02-20 | 2025-08-28 | 주식회사 종근당 | Parp1 억제제로서의 화합물 및 이를 포함하는 약학적 조성물 |
| WO2025248117A1 (en) | 2024-05-31 | 2025-12-04 | Astrazeneca Ab | 6-aminopurine derivatives useful as polq inhibitors |
| TW202547478A (zh) | 2024-05-31 | 2025-12-16 | 瑞典商阿斯特捷利康公司 | Ｐｏｌｑ抑制劑 |
| KR20260019426A (ko) | 2024-08-01 | 2026-02-10 | 주식회사 종근당 | Parp1 억제제로서의 화합물 및 이를 포함하는 약학적 조성물 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0699754T3 (da) | 1994-08-12 | 2001-02-26 | Myriad Genetics Inc | Fremgangsmåde til diagnosticering af prædisposition for bryst- og ovariecancer |
| EP0705903B2 (en) | 1994-08-12 | 2009-08-12 | The University of Utah Research Foundation | Mutations in the 17q-linked breast and ovarian cancer susceptibility gene |
| WO2003007959A1 (en) * | 2001-07-16 | 2003-01-30 | Fujisawa Pharmaceutical Co., Ltd. | Quinoxaline derivatives which have parp inhibitory action |
| BRPI0408284B8 (pt) | 2003-03-12 | 2021-05-25 | Kudos Pharm Ltd | compostos derivados de ftalazinona, seu uso e composição farmacêutica compreendendo os mesmos |
| JP2010507387A (ja) | 2006-10-25 | 2010-03-11 | クアーク・ファーマスーティカルス、インコーポレイテッド | 新規のｓｉＲＮＡおよびその使用方法 |
| US8048892B2 (en) | 2006-12-18 | 2011-11-01 | Amgen Inc. | Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof |
| JP2009196973A (ja) * | 2007-09-26 | 2009-09-03 | Santen Pharmaceut Co Ltd | キナゾリノン誘導体又はキノキサリン誘導体を有効成分として含有する後眼部疾患の予防又は治療剤 |
| US8404713B2 (en) * | 2007-10-26 | 2013-03-26 | Janssen Pharmaceutica Nv | Quinolinone derivatives as PARP inhibitors |
| KR101779137B1 (ko) | 2009-01-23 | 2017-09-18 | 다케다 야쿠힌 고교 가부시키가이샤 | 폴리(ａｄｐ-리보스)폴리머라제(ｐａｒｐ) 억제제 |
| WO2014045101A1 (en) * | 2012-09-21 | 2014-03-27 | Cellzome Gmbh | Tetrazolo quinoxaline derivatives as tankyrase inhibitors |
| HK1211033A1 (en) * | 2012-12-20 | 2016-05-13 | Bayer Pharma Aktiengesellschaft | Bet-protein-inhibiting dihydroquinoxalinones |
| EP2972381A2 (en) | 2013-03-14 | 2016-01-20 | Galapagos NV | Molecular targets and compounds, and methods to identify the same, useful in the treatment of diseases associated with epithelial mesenchymal transition |
| TWI772856B (zh) | 2013-07-19 | 2022-08-01 | 美商百健Ｍａ公司 | 用於調節τ蛋白表現之組合物 |
| PH12017502228B1 (en) * | 2015-06-09 | 2022-08-03 | Onconic Therapeutics Inc | Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same |
| MX2022000711A (es) | 2019-07-19 | 2022-02-23 | Astrazeneca Ab | Inhibidores de parp1. |
| US11795158B2 (en) * | 2020-06-25 | 2023-10-24 | Astrazeneca Ab | Chemical compounds |
-
2021
- 2021-06-22 US US17/354,322 patent/US11795158B2/en active Active
- 2021-06-24 CA CA3186996A patent/CA3186996A1/en active Pending
- 2021-06-24 UA UAA202300158A patent/UA130043C2/uk unknown
- 2021-06-24 EP EP21735690.6A patent/EP4172152A1/en active Pending
- 2021-06-24 CN CN202180043057.8A patent/CN115768760B/zh active Active
- 2021-06-24 JP JP2022579869A patent/JP7769650B2/ja active Active
- 2021-06-24 IL IL299123A patent/IL299123B2/en unknown
- 2021-06-24 WO PCT/EP2021/067304 patent/WO2021260092A1/en not_active Ceased
- 2021-06-24 MX MX2022015435A patent/MX2022015435A/es unknown
- 2021-06-24 KR KR1020237001972A patent/KR20230026450A/ko active Pending
- 2021-06-24 CN CN202610271871.XA patent/CN121873040A/zh active Pending
- 2021-06-24 BR BR112022025435A patent/BR112022025435A2/pt unknown
- 2021-06-24 CR CR20230024A patent/CR20230024A/es unknown
- 2021-06-24 AU AU2021295423A patent/AU2021295423B2/en active Active
- 2021-06-24 PE PE2022002989A patent/PE20231081A1/es unknown
- 2021-06-25 TW TW110123282A patent/TW202218664A/zh unknown
- 2021-06-25 UY UY0001039296A patent/UY39296A/es unknown
-
2022
- 2022-12-11 SA SA522441701A patent/SA522441701B1/ar unknown
- 2022-12-14 DO DO2022000288A patent/DOP2022000288A/es unknown
- 2022-12-22 CL CL2022003711A patent/CL2022003711A1/es unknown
-
2023
- 2023-01-10 CO CONC2023/0000186A patent/CO2023000186A2/es unknown
- 2023-01-20 ZA ZA2023/00924A patent/ZA202300924B/en unknown
- 2023-01-23 EC ECSENADI20235059A patent/ECSP23005059A/es unknown
- 2023-09-14 US US18/467,185 patent/US12421208B2/en active Active
-
2025
- 2025-08-12 US US19/297,723 patent/US20250368615A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2021260092A5 (https=) | ||
| JPWO2021013735A5 (https=) | ||
| EP2974728B1 (en) | Therapeutic agent for meibomian dysfunction | |
| JP2017533237A (ja) | 強力なγ−セクレターゼモジュレータ | |
| JP2020529995A (ja) | 行動の変化の治療方法 | |
| JP2003300884A (ja) | ＴＮＦ−α産生阻害剤 | |
| EP4520752A1 (en) | Carebastine salt and use thereof | |
| ES2210399T3 (es) | Farmacos para profilaxis/tratamiento de las complicaciones de la diabetes. | |
| AU731274B2 (en) | Anticancer composition comprising a diaminotrifluoromethylpyridine derivative | |
| US8604212B2 (en) | Anti-shock agent comprising diaminotrifluoromethylpyridine derivative | |
| EP4349341A1 (en) | Pharmaceutical preparation for preventing or treating pulmonary fibrosis | |
| JP3450399B2 (ja) | 血管新生阻害剤 | |
| WO2003090746A1 (en) | 1,3-thiazoles as lxr modulators in the treatment of cardiovascular diseases | |
| JP2000517342A (ja) | 結晶性医薬品 | |
| JPH1017471A (ja) | ピリジン化合物系併用医薬 | |
| JPWO2023207283A5 (https=) | ||
| KR20210046115A (ko) | 니아신 유도체 및 이를 함유하는 약학 조성물 | |
| JP2010150243A (ja) | ピリジン−３−カルバルデヒドｏ−（ピペリジン−１−イル−プロピル）−オキシム誘導体を有効成分として含有する網脈絡膜変性疾患の治療剤 | |
| CN111303161B (zh) | 嘧啶并氮杂环类化合物及其用途 | |
| JP4598674B2 (ja) | 統合失調症治療剤 | |
| TW202408499A (zh) | 降低血中肌肉生長抑制素之藥劑 | |
| US20070232614A1 (en) | Therapeutic Agent for Nonviral Hepatitis | |
| WO2022261627A1 (en) | Inhibitors of ttbk1 | |
| JPH1017470A (ja) | ピリジン系併用医薬 | |
| JP2702284B2 (ja) | ソマトスタチン増加用またはソマトスタチン低下抑制用薬剤 |